FREMONT, CA , Dec. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (“ABVC” or the “Company”) (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today shared an interview with Dr. Scott Irwin, MD, Ph.D., an eminent Professor of Psychiatry and Behavioral Neurosciences at Cedars-Sinai Medical Center (CSMC). Dr. Irwin serves as the Principal Investigator for the clinical trials of ABV-1601, the Company’s drug under development to treat depression in cancer patients.

“Dr. Irwin is trustworthy, sincere, devoted to the work, and takes things that concern his patients seriously. We are grateful for him joining our study as the principal investigator,” said Uttam Patil, Ph.D., Chief Executive Officer of ABVC. He added that the Company believes Dr. Irwin’s ideas and comments will aid in completing the trials on a positive note.

Follow the link to hear the full interview with Dr. Irwin and to learn about why patients are taking lots of medications and looking for something natural to treat their depression.

ABVC BioPharma Website Link
Youtube Channel Link

According to Global Market Insights, Antidepressant Drugs Market size exceeded USD 13.5 billion in 2020 and is anticipated to grow at over 7.2% CAGR between 2021 and 2027.[1]

About ABVC BioPharma

ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company’s network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct global pivotal clinical trials for PMA (pre-Market Approval).

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Contact:
Leeds Chow
Email: This email address is being protected from spambots. You need JavaScript enabled to view it. 

[1] https://www.gminsights.com/industry-analysis/antidepressant-drugs-market